Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition
November 02 2023 - 9:00AM
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage
biopharmaceutical company focused on developing and commercializing
novel therapeutics to treat a wide range of patients with disorders
that are linked to dysfunctional signaling of the transforming
growth factor-beta (“TGF-ß”) family of proteins, today announced
that five abstracts will be presented from its hematology program
at the 65th American Society of Hematology (“ASH”) Annual Meeting
and Exposition to be held in person and virtually from December 9
through 12, 2023. Keros will be presenting additional results from
its two ongoing Phase 2 clinical trials of KER-050, one in patients
with very low-, low-, or intermediate-risk myelodysplastic syndrome
(“MDS”) and one in patients with myelofibrosis.
The following abstracts were posted to the ASH website on
November 2, 2023, 9:00 a.m. Eastern time.
Clinical Presentations
“Durable Clinical Benefit with KER-050 treatment:
Findings From an Ongoing Phase 2 Study in Participants with
Lower-Risk MDS”
- Publication Number:
196
- Session Name: 637.
MDS Clinical and Epidemiological: Treatment Options and Decision
making in Low Risk MDS
- Date: Saturday,
December 9, 2023
- Presentation Time:
2:00 p.m. – 4:00 p.m. Pacific time
“Modulation of TGF-β Superfamily Signaling By KER-050
Demonstrated Potential to Treat Myelofibrosis and Mitigate
Ruxolitinib-Associated Cytopenia”
- Publication Number:
3185
- Session Name: 634.
Myeloproliferative Syndromes: Clinical and Epidemiological: Poster
II
- Date: Sunday,
December 10, 2023
- Presentation Time:
6:00 p.m. – 8:00 p.m. Pacific time
“KER-050 Treatment Reduced Iron Overload and Increased
Bone Specific Alkaline Phosphatase in Participants with Lower-Risk
MDS Supporting Potential to Restore Balance to the
Osteohematopoietic Niche”
- Publication Number:
1089
- Session Name: 102.
Iron Homeostasis and Biology
- Date: Saturday,
December 9, 2023
- Presentation Time:
6:00 p.m. – 8:00 p.m. Pacific time
Preclinical Presentations
“RKER-050, A Modified Activin Receptor Type IIA Ligand
Trap, Promoted Erythropoiesis in a Murine Model of
Myelofibrosis”
- Publication Number:
4524
- Session Name: 631.
Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic
and Translational: Poster III
- Date: Monday,
December 11, 2023
- Presentation Time:
6:00 p.m. – 8:00 p.m. Pacific time
“RKER-216 Reversed Microcytic Anemia in a Mouse Model of
Iron Refractory Iron Deficiency Anemia”
- Publication Number:
2466
- Session Name: 102.
Iron Homeostasis and Biology: Poster II
- Date: Sunday,
December 10, 2023
- Presentation Time:
6:00 p.m. – 8:00 p.m. Pacific time
About KER-050
Keros’ lead protein therapeutic product candidate, KER-050, is
an engineered ligand trap comprised of a modified ligand-binding
domain of the TGF-ß receptor known as activin receptor type IIA
that is fused to the portion of the human antibody known as the Fc
domain. KER-050 is being developed for the treatment of low blood
cell counts, or cytopenias, including anemia and thrombocytopenia,
in patients with MDS and in patients with myelofibrosis.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on
developing and commercializing novel therapeutics to treat a wide
range of patients with disorders that are linked to dysfunctional
signaling of the TGF-ß family of proteins. We are a leader in
understanding the role of the TGF-ß family of proteins, which are
master regulators of the growth, repair and maintenance of blood
cells and a number of tissues, including bone, skeletal muscle,
adipose and heart tissue. By leveraging this understanding, we have
discovered and are developing large and small molecules that have
the potential to provide meaningful and potentially
disease-modifying benefit to patients. Keros’ lead protein
therapeutic product candidate, KER-050, is being developed for the
treatment of low blood cell counts, or cytopenias, including anemia
and thrombocytopenia, in patients with MDS and in patients with
myelofibrosis. Keros’ lead small molecule product candidate,
KER-047, is being developed for the treatment of functional iron
deficiency. Keros’ third product candidate, KER-012, is being
developed for the treatment of pulmonary arterial hypertension and
for the treatment of cardiovascular disorders. Keros’ fourth
product candidate, KER-065, is being developed for the treatment of
neuromuscular diseases, with an initial focus on Duchenne muscular
dystrophy.
Cautionary Note Regarding Forward-Looking
Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Words such as “believe,” “can,” “look
forward,” “potential” and/or similar expressions are intended to
identify forward-looking statements. Examples of these
forward-looking statements include statements concerning: Keros’
presentation plans for the upcoming ASH Annual Meeting and
Exposition. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
risks and uncertainties include, among others: Keros’ limited
operating history and historical losses; Keros’ ability to raise
additional funding to complete the development and any
commercialization of its product candidates; Keros’ dependence on
the success of its product candidates, KER-050, KER-047, KER-012
and KER-065; that Keros may be delayed in initiating, enrolling or
completing any clinical trials; competition from third parties that
are developing products for similar uses; Keros’ ability to obtain,
maintain and protect its intellectual property; and Keros’
dependence on third parties in connection with manufacturing,
clinical trials and preclinical studies.
These and other risks are described more fully in Keros’ filings
with the Securities and Exchange Commission (“SEC”), including the
“Risk Factors” section of the Company’s Quarterly Report on Form
10-Q, filed with the SEC on August 7, 2023, and its other documents
subsequently filed with or furnished to the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except to the extent
required by law, Keros undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Investor Contact:Justin
Frantzjfrantz@kerostx.com617-221-6042
Keros Therapeutics (NASDAQ:KROS)
Historical Stock Chart
From Apr 2024 to May 2024
Keros Therapeutics (NASDAQ:KROS)
Historical Stock Chart
From May 2023 to May 2024